Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (23)

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  3. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

2021

  1. Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 7, pp. 1037-1049

  2. Accelerated long-term forgetting over three months in asymptomatic APOE ɛ4 carriers

    Annals of Clinical and Translational Neurology, Vol. 8, Núm. 2, pp. 477-484

  3. Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals

    Proteomes, Vol. 9, Núm. 3

  4. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

  5. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

2020

  1. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  2. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  3. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics

    Brain, Vol. 143, Núm. 12, pp. 3776-3792

2019

  1. Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity

    Cortex, Vol. 121, pp. 117-124

  2. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

    Alzheimer's and Dementia, Vol. 15, Núm. 10, pp. 1333-1347

  3. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 742-753

2018

  1. Cortical microstructural changes along the Alzheimer's disease continuum

    Alzheimer's and Dementia, Vol. 14, Núm. 3, pp. 340-351

  2. The EMIF-AD Multimodal Biomarker Discovery study: Design, methods and cohort characteristics

    Alzheimer's Research and Therapy, Vol. 10, Núm. 1

2017

  1. Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1

    Journal of Alzheimer's Disease, Vol. 58, Núm. 3, pp. 855-870

2016

  1. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

    Alzheimer's and Dementia, Vol. 12, Núm. 2, pp. 154-163

2015

  1. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

    Brain, Vol. 138, Núm. 9, pp. 2701-2715

  2. Recomendaciones para la utilización de biomarcadores de imagen PET en el proceso diagnóstico de las enfermedades neurodegenerativas que cursan con demencia: Documento de consenso SEMNIM y SEN

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 34, Núm. 5, pp. 303-313